59394-30-8

Usage

Uses

Used in Pharmaceutical Synthesis:
6-Chloroquinoline-2-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be incorporated into a wide range of drug molecules, contributing to their therapeutic properties.
Used in Agrochemical Production:
6-CHLOROQUINOLINE-2-CARBOXYLIC ACID is also used as a building block in the production of various agrochemicals. Its incorporation into agrochemical formulations can enhance their effectiveness in controlling pests and diseases in agriculture.
Used in Organic Synthesis:
6-Chloroquinoline-2-carboxylic acid is used as a reagent in organic synthesis. Its presence in various organic reactions can facilitate the formation of desired products, making it a useful tool for chemists in the synthesis of complex organic compounds.
Used in the Preparation of Heterocyclic Compounds:
6-CHLOROQUINOLINE-2-CARBOXYLIC ACID is utilized in the preparation of heterocyclic compounds, which are an important class of organic compounds with diverse applications in pharmaceuticals, materials science, and other fields.
Used in Antifungal Applications:
6-Chloroquinoline-2-carboxylic acid has been studied for its antifungal properties, making it a potential candidate for use in antifungal agents. Its ability to inhibit fungal growth can be beneficial in treating various fungal infections.
Used in Anti-inflammatory Applications:
6-CHLOROQUINOLINE-2-CARBOXYLIC ACID has also been studied for its anti-inflammatory properties, suggesting its potential use in the development of anti-inflammatory drugs. Its ability to reduce inflammation can be advantageous in managing various inflammatory conditions.

Upstream product

• 612-57-7 6-chloroquinoline 
• 20028-53-9 2-amino-5-chlorobenzaldehyde 
• 57-60-3 piruvate 
• 6628-86-0 5-chloro-2-nitrobenzaldehyde 
• 92-46-6 6-chloro-2-methylquinoline 
• 59394-26-2 6-chloroquinoline-2-carbaldehyde 
• 52313-35-6 6-chloroquinoline-2-carbonitrile 

Downstream Products

• 480449-95-4 (1S,2R,4S)-N₂-(tert-Butoxycarbonyl)-N₁-[(6-chloro-quinolin-2-yl)carbonyl]-4-(N,N-dimethylcarbamoyl)-1,2-cyclohexanediamine 

Relevant academic research and scientific papers

Repurposing an Aldolase for the Chemoenzymatic Synthesis of Substituted Quinolines

Quinoline derivatives are important natural products and pharmaceuticals, but their synthesis can be challenging due to poor yields, harsh reaction conditions, and instability of starting materials. Here we report the chemoenzymatic synthesis of quinaldic acids under mild conditions using an aldolase, trans-o-hydroxybenzylidenepyruvate hydratase-aldolase (NahE, or HBPA). A series of 2-aminobenzaldehydes derived from reduction of the corresponding nitro analogue were reacted with pyruvate in the presence of NahE to give substituted quinolines in up to 93% isolated yield. This reaction differs from the aldol condensation catalyzed by NahE in vivo, instead resembling the heterocycle formation catalyzed by its homologue, dihydrodipicolinate synthase.

Silyl Assistance in the Intramolecular Addition of Pyridyl Radicals onto Pyridines and Quinolines

The first example of a stable acylazinium salt obtained by an intramolecular acylpyridine-centered radical attack on azine nitrogen atoms is reported. Depending on the relative position of the bromo substituent on the attacking aminopyridine ring, it is possible to obtain selectively either the N-attack product or a different C-attack derivative. A rationale for this pathway selectivity was obtained from quantum mechanical calculations.

Synthesis of lodopyridone

The total synthesis of the unusual 4-pyridone marine metabolite lodopyridone has been achieved by late stage manipulation of the related 4-pyrone. Key reactions include a Suzuki-Miyaura coupling to form the tetracyclic core and a modified Corey-Ganem-Gilman reaction to install the ethanolamide side-chain.

Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: Exploration of 6-6 fused rings as alternative S1 moieties

A series of cis-1,2-diaminocyclohexane derivatives possessing a 6-6 fused ring for the S1 moiety were synthesized as novel factor Xa (fXa) inhibitors. The synthesis, structure-activity relationship (SAR), and physicochemical properties are reported herein, together with the discovery of compound 45c, which has potent anti-fXa activity, good physicochemical properties and pharmacokinetic (PK) profiles, including a reduced negative food effect.

5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine

The invention concerns novel 5-sulphanyl-4H-1,2,4-triazole derivatives of formula (1), wherein: R1, R2 and R3 represent variable groups and the methods for preparing them by liquid-phase parallel synthesis processes. Said product exhibit good affinity for certain sub-types of somatostatin receptors; they are particularly useful for treating pathological conditions or diseases wherein one (or more) somatostatin receptors is (are) involved. The invention also concerns pharmaceutical compositions containing said products and their use for preparing a medicine.

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

ETHYLENEDIAMINE DERIVATIVES

The invention relates a compound represented by the formula (1):Q1-Q2-C(=O)-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents -CO- or -SO2-, and a medicine which comprises the compound and is useful for thrombosis and embolism.

1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids

A series of 1-[acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids and salts thereof are useful as Angiotensin I converting enzyme inhibitors.